• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024

    12/13/24 6:00:00 PM ET
    $VRDN
    Medical Specialities
    Health Care
    Get the next $VRDN alert in real time by email

    - THRIVE-2 global phase 3 clinical trial evaluated efficacy and safety of veligrotug in patients with chronic thyroid eye disease (TED) -

    - Conference call and webcast to be held Monday, December 16, at 8:00 a.m. ET -

    Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced plans to host a conference call and webcast to report topline data for the THRIVE-2 phase 3 clinical trial, evaluating veligrotug in chronic TED, on Monday, December 16, 2024 at 8:00am ET.

    Conference call and webcast information

    The webcast can be accessed under "Events and Presentations" on the Investors section of the Viridian website at viridiantherapeutics.com. To participate in the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference code 9934051. A replay of the webcast will be available following the completion of the event.

    About Viridian Therapeutics

    Viridian is a biopharmaceutical company focused on engineering and developing potential best-in-class medicines for patients with serious and rare diseases. Viridian's expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas.

    Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The company is conducting a pivotal program for veligrotug (VRDN-001), including two global phase 3 clinical trials (THRIVE and THRIVE-2), to evaluate its efficacy and safety in patients with active and chronic TED. Viridian is also advancing VRDN-003 as a potential best-in-class subcutaneous therapy for the treatment of TED, including two ongoing global phase 3 pivotal clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients with active and chronic TED.

    In addition to its TED portfolio, Viridian is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.

    Viridian is based in Waltham, Massachusetts. For more information, please visit www.viridiantherapeutics.com. Follow Viridian on LinkedIn and X.

    Forward Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as, but not limited to, "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "on track," "plan," "potential," "predict," "project," "design," "should," "target," "will," or "would" or other similar terms or expressions that concern our expectations, plans and intentions. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations, and assumptions. Forward-looking statements include, without limitation, statements regarding: preclinical and clinical development of Viridian's product candidates veligrotug (formerly VRDN-001), VRDN-003, VRDN-006 and VRDN-008; Viridian's product candidates potentially being best-in-class; and the potential for Viridian's product candidates to be developed in multiple autoimmune diseases.

    New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to the potential utility, efficacy, potency, safety, clinical benefits, clinical response and convenience of Viridian's product candidates and those risks set forth under the caption "Risk Factors" in our most recent quarterly report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on November 12, 2024 and other subsequent disclosure documents filed with the SEC. Any forward-looking statement speaks only as of the date on which it was made. Neither the company, nor its affiliates, advisors, or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing the company's views as of any date subsequent to the date hereof.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241213672239/en/

    Get the next $VRDN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VRDN

    DatePrice TargetRatingAnalyst
    8/25/2025$44.00Buy
    Jefferies
    12/19/2024$37.00 → $27.00Overweight → Equal Weight
    Wells Fargo
    11/25/2024Buy
    TD Cowen
    9/11/2024$30.00 → $38.00Buy
    Needham
    6/11/2024$29.00Outperform
    Wolfe Research
    6/6/2024$23.00Buy
    Goldman
    5/9/2024Buy → Neutral
    Ladenburg Thalmann
    5/9/2024$25.00 → $20.00Buy → Neutral
    B. Riley Securities
    More analyst ratings

    $VRDN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Beetham Thomas W. bought $117,050 worth of shares (5,000 units at $23.41), increasing direct ownership by 500% to 6,000 units (SEC Form 4)

    4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)

    9/30/24 7:12:50 PM ET
    $VRDN
    Medical Specialities
    Health Care

    President and CEO Mahoney Stephen F. bought $499,262 worth of shares (21,400 units at $23.33) (SEC Form 4)

    4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)

    9/30/24 7:10:58 PM ET
    $VRDN
    Medical Specialities
    Health Care

    Director Fairmount Funds Management Llc bought $30,000,000 worth of shares (1,600,000 units at $18.75) (SEC Form 4)

    4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)

    9/17/24 9:00:13 PM ET
    $VRDN
    Medical Specialities
    Health Care

    $VRDN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Cain Christopher W.

    4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)

    7/2/25 4:48:31 PM ET
    $VRDN
    Medical Specialities
    Health Care

    SEC Form 4 filed by Director Kiselak Tomas

    4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)

    7/2/25 4:46:45 PM ET
    $VRDN
    Medical Specialities
    Health Care

    SEC Form 4 filed by Director Morris Arlene

    4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)

    7/2/25 4:45:26 PM ET
    $VRDN
    Medical Specialities
    Health Care

    $VRDN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Viridian Therapeutics Announces Proposed Underwritten Public Offering

    Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today announced that it has commenced an underwritten public offering of shares of its common stock and Series B non-voting convertible preferred stock. All of the securities to be sold in the underwritten public offering are being offered by Viridian. In addition, Viridian intends to grant the underwriters a 30-day option to purchase additional shares of its common stock. Each share of Series B preferred stock will be convertible into 66.67 shares of common stock at the election of the holder, subject to b

    10/21/25 4:01:00 PM ET
    $VRDN
    Medical Specialities
    Health Care

    DRI Healthcare Trust Announces Acquisition of a Synthetic Royalty Interest in the U.S. Sales of Veligrotug and VRDN-003 for the Treatment of Thyroid Eye Disease (TED)

    –Third synthetic royalty transaction & second pre-approval deal for DRI –– Further increases portfolio exposure to rare diseases ––  Long-dated cashflows, extend portfolio duration –– DRI Healthcare to pay US$55 million upfront; up to US$300 million total investment, subject to achievement of certain milestones– TORONTO, Oct. 20, 2025 /CNW/ - DRI Healthcare Trust (TSX:DHT) (TSX:DHT) ("DRI Healthcare"), a global leader in providing financing to advance innovation in the life sciences industry, has acquired a royalty interest in the U.S. net sales of veligrotug (formerly known as VRDN-001) and VRDN-003 from Viridian Therapeutics, Inc. (NASDAQ:VRDN) for an aggregate purchase price of up to US$3

    10/20/25 7:30:00 AM ET
    $VRDN
    Medical Specialities
    Health Care

    Viridian Therapeutics Announces Royalty Financing with DRI Healthcare for up to $300 Million

    - Viridian receives $55 million upfront and potential near-term milestones up to $115 million based on positive VRDN-003 topline data and U.S. veligrotug marketing approval - - Upfront and anticipated near-term milestones together with existing cash expected to fully fund the commercial launches of both veligrotug and VRDN-003 - - Veligrotug Biologics License Application (BLA) submission expected imminently; VRDN-003 phase 3 clinical trial topline data readouts now expected Q1 2026 for REVEAL-1 and Q2 2026 for REVEAL-2 - - Amended credit facility with Hercules Capital, Inc., providing additional access to capital at the company's discretion based on milestone achievements - Viridian

    10/20/25 7:30:00 AM ET
    $VRDN
    Medical Specialities
    Health Care

    $VRDN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies resumed coverage on Viridian Therapeutics with a new price target

    Jefferies resumed coverage of Viridian Therapeutics with a rating of Buy and set a new price target of $44.00

    8/25/25 8:56:04 AM ET
    $VRDN
    Medical Specialities
    Health Care

    Viridian Therapeutics downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Viridian Therapeutics from Overweight to Equal Weight and set a new price target of $27.00 from $37.00 previously

    12/19/24 8:33:15 AM ET
    $VRDN
    Medical Specialities
    Health Care

    TD Cowen initiated coverage on Viridian Therapeutics

    TD Cowen initiated coverage of Viridian Therapeutics with a rating of Buy

    11/25/24 7:56:18 AM ET
    $VRDN
    Medical Specialities
    Health Care

    $VRDN
    SEC Filings

    View All

    SEC Form 424B5 filed by Viridian Therapeutics Inc.

    424B5 - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)

    10/21/25 4:36:52 PM ET
    $VRDN
    Medical Specialities
    Health Care

    Viridian Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)

    10/21/25 4:35:06 PM ET
    $VRDN
    Medical Specialities
    Health Care

    SEC Form 8-K filed by Viridian Therapeutics Inc.

    8-K - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)

    10/20/25 7:42:37 AM ET
    $VRDN
    Medical Specialities
    Health Care

    $VRDN
    Leadership Updates

    Live Leadership Updates

    View All

    Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results

    - Biologics License Application (BLA) submission for veligrotug on track for second half 2025 with potential for U.S. launch in 2026; preparatory commercial activities underway - - REVEAL-1 and REVEAL-2, phase 3 clinical trials assessing VRDN-003 in active and chronic thyroid eye disease (TED), are on track for topline data in the first half of 2026 - - VRDN-006 clinical data in healthy volunteers on track for third quarter 2025 - - VRDN-008, a bispecific neonatal Fc receptor (FcRn) inhibitor with an extended half-life, on track for an Investigational New Drug (IND) submission for year-end 2025 - - Appointed Jeff Ajer, long-time Chief Commercial Officer of BioMarin, to Viridian's Board

    5/6/25 7:00:00 AM ET
    $VRDN
    Medical Specialities
    Health Care

    Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors

    - Mr. Ajer was most recently Chief Commercial Officer at BioMarin - Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the appointment of Jeff Ajer to its Board of Directors. Mr. Ajer has more than 25 years of experience driving commercialization for rare diseases and specialty medicines, including leading commercial planning for late-stage pipeline programs, product marketing, reimbursement, and sales operations. He most recently served as the Executive Vice President and Chief Commercial Officer (CCO) at BioMarin Pharmaceutical, where he joined in 20

    4/7/25 7:00:00 AM ET
    $VRDN
    Medical Specialities
    Health Care

    Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results

    - Reported positive topline phase 3 data for veligrotug from both THRIVE and THRIVE-2 in patients with active and chronic thyroid eye disease (TED); veligrotug has the potential to transform the standard of care in TED with a differentiated clinical profile achieved with fewer infusions; Biologics License Application (BLA) submission on track for second half of 2025 - - REVEAL-1 and REVEAL-2, phase 3 clinical trials assessing Q4W or Q8W subcutaneous (SC) VRDN-003 in active and chronic TED, progressing as planned and on track for topline data for both trials in the first half of 2026 - - Proof-of-concept IgG reduction clinical data in healthy volunteers anticipated in the third quarter o

    2/27/25 7:00:00 AM ET
    $VRDN
    Medical Specialities
    Health Care

    $VRDN
    Financials

    Live finance-specific insights

    View All

    Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease

    - Veligrotug met all primary and secondary endpoints with high statistical significance in THRIVE-2, achieving a week 15 proptosis responder rate (PRR) of 56% (placebo-adjusted PRR of 48%, p < 0.0001) - - THRIVE-2 is the first global phase 3 study in patients with chronic TED to demonstrate a statistically significant and clinically meaningful 56% diplopia responder rate (placebo-adjusted rate of 31%, p = 0.0006) and 32% rate of diplopia complete resolution (placebo-adjusted rate of 18%, p = 0.0152) - - Veligrotug was generally well-tolerated with 94% of patients completing their treatment course and a 9.6% placebo-adjusted rate of hearing impairment - - BLA submission for veligrotug

    12/16/24 7:00:00 AM ET
    $VRDN
    Medical Specialities
    Health Care

    Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024

    - THRIVE-2 global phase 3 clinical trial evaluated efficacy and safety of veligrotug in patients with chronic thyroid eye disease (TED) - - Conference call and webcast to be held Monday, December 16, at 8:00 a.m. ET - Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced plans to host a conference call and webcast to report topline data for the THRIVE-2 phase 3 clinical trial, evaluating veligrotug in chronic TED, on Monday, December 16, 2024 at 8:00am ET. Conference call and webcast information The webcast can be accessed under "Events and Presenta

    12/13/24 6:00:00 PM ET
    $VRDN
    Medical Specialities
    Health Care

    Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease

    - Veligrotug (VRDN-001) achieved all primary and secondary endpoints in THRIVE, the largest phase 3 trial conducted to date of an anti-IGF-1R antibody in thyroid eye disease (TED), with a week 15 proptosis responder rate (PRR) of 70% and a placebo-adjusted PRR of 64% (p < 0.0001) - - All secondary endpoints were highly statistically significant (p < 0.0001), with clinically meaningful patient outcomes, including complete resolution of diplopia in 54% of patients (placebo-adjusted rate of 43%) and reduction of Clinical Activity Score (CAS) to 0 or 1 in 64% of patients (placebo-adjusted reduction of 46%) treated with veligrotug - - Veligrotug was generally well-tolerated with no treatment-r

    9/10/24 7:00:00 AM ET
    $VRDN
    Medical Specialities
    Health Care

    $VRDN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Viridian Therapeutics Inc.

    SC 13G/A - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)

    11/14/24 5:53:44 PM ET
    $VRDN
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Viridian Therapeutics Inc.

    SC 13G/A - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)

    11/14/24 5:52:18 PM ET
    $VRDN
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Viridian Therapeutics Inc.

    SC 13G/A - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)

    11/14/24 4:50:30 PM ET
    $VRDN
    Medical Specialities
    Health Care